Boehringer Ingelheim says growth is due to medicines
22 April 2009 00:00 in Pharmaceutical Company Product News
Boehringer Ingelheim achieved its goals for last year largely due to its prescription medicines, it has claimed.
Compared to the pharmaceutical market as a whole, the company grew stronger and its net sales rose from 10.9 billion euros (9.6 billion pounds) in 2007 to 11.6 billion euros.
Some 79 per cent of the business' net sales came from prescription medicines.
Its drug Spriva ? designed to treat chronic obstructive pulmonary disease ? achieved a turnover of more than two billion euros and treated over ten million patients.
Engelbert Tjeenk Willink is responsible for the corporate board division of the company's pharmaceutical marketing and sales.
Mr Willink commented: "Our growth in 2008 again gratifyingly exceeded the world pharmaceutical market in all three regions.
"Our innovative products have good potential for the future."
Member of the board of directors Andreas Barner added the firm is confident it can continue the success over the next 12 months, with further strong sales in its prescription medicines.
Last month, Boehringer Ingelheim completed phase III clinical trials of its randomised evaluation of long-term anticoagulant therapy study.
Other news stories from 22/04/2009
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency